Lv3
390 积分 2023-05-10 加入
Assessment of disease activity and damage in SLE: Are we there yet?
12天前
已完结
Protein degraders enter the clinic — a new approach to cancer therapy
13天前
已完结
Extracellular targeted protein degradation: an emerging modality for drug discovery
13天前
已完结
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
15天前
已完结
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind, Randomized, Placebo‐Controlled, Phase 2 Trial
15天前
已完结
Precision medicine in systemic lupus erythematosus
18天前
已完结
CAR T therapy beyond cancer: the evolution of a living drug
18天前
已完结
Delivering on the promise of protein degraders
20天前
已完结
BTK degraders tackle drug resistance
20天前
已完结
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies
20天前
已完结
皖公网安备34019202002308
